Clinical Trial Update: A Phase Ib Study of Novel Combination (New) of Low Dose Oral CyclophoSphamide (s) to Potentiate Axatilimab (A) + Retifanlimab (R) in Treating Metastatic Triple Negative Breast Cancer (TNBC) [Phase 1]

View source ↗

Summary

Phase Ib study evaluating a low-dose oral cyclophosphamide to potentiate axatilimab and retifanlimab in metastatic triple-negative breast cancer. Recruitment is…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• Axatilimab (axatilimab)
• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Retifanlimab (retifanlimab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Breast Cancer | Phase 1 | Status: RECRUITING